|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||21.02 - 21.40|
|52 Week Range||10.60 - 24.96|
|Beta (5Y Monthly)||1.57|
|PE Ratio (TTM)||235.78|
|Earnings Date||Aug 07, 2023 - Aug 11, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.83|
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Reiterates 2023 Financial GuidancePRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. First Quarter Highlights: Revenue was $90.3 million, compared to $81.6 million in the first quarter of 2022, representing growth of 11% over the first quarter of 2022 on a reported basis and 13% at constant currency.Net income was $1.4 million, compared to $2.2 million in
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atlassian's (TEAM) Q3 results are likely to reflect the benefits of increased demand for its solutions amid accelerated digital transformations and cloud adoptions.
DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.
Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara are included in this Analyst Blog.
We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.
Asserts Certara’s leadership in advancing the development and approval of new drugs for patientsPRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received by Certara’s customers in 2022.* This is the 9th consecutive year that Certara’s customers, who use the Company’s biosimulatio
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara als
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
CERT, BWMX and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 15, 2023.
Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A.I. will enable discovery scientists to integrate multiple structured and unstructured data sources and substantia
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studiesPRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated
Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?